M&A Deal Summary |
|
|---|---|
| Date | 2025-06-27 |
| Target | European Orladeyo Berotralstat business |
| Sector | Life Science |
| Buyer(s) | Neopharmed Gentili |
| Sellers(s) | BioCryst Pharmaceuticals |
| Deal Type | Divestiture |
| Deal Value | 264M USD |
SEARCH BY
| Category | Company |
|---|---|
| Founded | 2011 |
| Sector | Life Science |
| Revenue | 192M EUR (2017) |
Neopharmed Gentili is an Italian pharmaceutical group focused on the research, development, production, and distribution of medicines in many therapeutic areas such as vascular and cardio-metabolic areas, pneumatological areas, antibiotics, OTCs, and supplements. Neopharmed Gentili was founded in 2011 and is based in Milan, Italy.
| DEAL STATS | # |
|---|---|
| Overall | 2 of 2 |
| Sector: Life Science M&A | 2 of 2 |
| Type: Divestiture M&A Deals | 1 of 1 |
| State: North Carolina M&A | 1 of 1 |
| Country: United States M&A | 1 of 1 |
| Year: 2025 M&A | 1 of 1 |
| Size (of disclosed) | 1 of 1 |
| DATE | TARGET | DEAL TYPE | VALUE |
|---|---|---|---|
| 2019-10-31 |
MDM
Monza, Italy MDM S.p.A. a pharmaceutical company based in Monza active in the distribution of pharmaceuticals, nutraceuticals and medical devices for neurology and orthopedics. |
Buy | - |
| Category | Company |
|---|---|
| Founded | 1986 |
| Sector | Life Science |
| Employees | 580 |
| Revenue | 451M USD (2024) |
BioCryst Pharmaceuticals designs, optimizes and develops novel small molecule drugs that block key enzymes involved in rare diseases. BioCryst Pharmaceuticals was founded in 1986 and is based in Durham, North Carolina.
| DEAL STATS | # |
|---|---|
| Overall | 1 of 1 |
| Sector: Life Science M&A | 1 of 1 |
| Type: Divestiture M&A Deals | 1 of 1 |
| State: North Carolina M&A | 1 of 1 |
| Country: United States M&A | 1 of 1 |
| Year: 2025 M&A | 1 of 1 |
| Size (of disclosed) | 1 of 1 |
| DATE | TARGET | DEAL TYPE | VALUE |
|---|---|---|---|
| 2012-10-18 |
Presidio Pharmaceuticals
San Francisco, California, United States Presidio Pharmaceuticals is a specialty pharmaceutical company focusing on in-licensing, developing, and commercializing novel and validated therapeutics for chronic viral infections, including HIV-1, HCV, and CMV. Presidio Pharmaceuticals was founded in 2006 and is based in San Francisco, California. |
Buy | $101M |
| DATE | TARGET | DEAL TYPE | VALUE |
|---|---|---|---|
| 2025-10-14 |
Astria
Boston, Massachusetts, United States Astria is a biopharmaceutical company focused on developing life-changing therapies for allergic and immunologic diseases. The company's lead program, navenibart (STAR-0215), is a monoclonal antibody inhibitor of plasma kallikrein in clinical development for the treatment of hereditary angioedema. Its second program, STAR-0310, is an investigational monoclonal antibody OX40 antagonist in clinical development for the treatment of atopic dermatitis. Astria was founded in 2008 and is based in Boston, Massachusetts. |
Buy | $700M |
